Protecting biomarkers and personalised/stratified medicine

Interest in the promise of biomarkers and personalised/stratified medicine is building. In the UK, for example, the government announced a Diagnostics for Stratified Medicine Catapult centre in August 2013, and partners including the Technology Strategy Board and the Medical Research Council have committed to spend more than £200 million ($336 million) over a five-year period to promote the development of stratified medicine, providing the tools, processes and systems for identifying the right therapy for the right patient, at the right time and at the right dose.